Experimental diabetic nephropathy: Is it relevant to the human disease

Nephrology

Volumn 5, Issue 3, 2000, Pages 177-185

  Kelly, Darren J ^a   Allen, Terri J ^a   Cooper, Mark E ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Diabetes; Haemodynamic; Metabolic; Nephropathy; Rat growth factors

Indexed keywords

ADVANCED GLYCATION END PRODUCT; GLUCOSE; HORMONE RECEPTOR; PROTEIN KINASE C; TRANSFORMING GROWTH FACTOR BETA; VASOACTIVE AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; BLOOD PRESSURE REGULATION; DIABETIC NEPHROPATHY; GLOMERULUS FILTRATION RATE; GLUCOSE BLOOD LEVEL; HYPERGLYCEMIA; KIDNEY FAILURE; KIDNEY HYPERTROPHY; MOUSE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEINURIA; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RENOVASCULAR HYPERTENSION; REVIEW;

EID: 0033638396     PISSN: 13205358     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1440-1797.2000.00003.x     Document Type: Review

References (105)

1. Diabetic glomerulopathy in man and experimental animal models
2. Prevention of diabetic glomerulopathy in streptozotocin diabetic rats by insulin treatment. Kidney size and glomerular Volume
3. Induction of malignant kidney tumours in rats with streptozotocin
4. Pathogenesis, prevention, and treatment of diabetic nephropathy
5. A baboon (Papio hamadryas) model of insulin-dependent diabetes
6. Development of glomerular lesions in experimental long-term diabetes in the rat
7. Glomerular filtration rate in the streptozotocin diabetic rat: The role of exchangeable sodium, vasoactive hormones and insulin therapy
8. Increased kidney size and glomerular filtration rate in early juvenile diabetes
9. Effects of genetic hypertension on diabetic nephropathy in the rat - Functional and structural characteristics
10. The stages in diabetic renal disease. With special emphasis in the stage of incipient diabetic nephropathy
11. Short and long term effects of antihypertensive therapy in the diabetic rat
12. A new model of progressive diabetic renal impairment in the transgenic (mRen-2)27 rat
13. Renal papillary necrosis: An update
14. Animal models of spontaneous diabetic kidney disease
15. Glomerular manifestations of diabetes in the BB rats
16. Glomerulopathy in spontaneously diabetic rat. Impact of glycaemic control
17. Rodent models of nephropathy associated with type I1 diabetes
18. Mesangial expansion as a central mechanism for loss of kidney function in diabetic patients
19. Breeding and characteristics of a spontaneously diabetic non-obese strain (NOD mouse) of mice
20. Evolution of renal function abnormalities in the db/db mouse that parallels the development of human diabetic nephropathy
21. Involvement of angiotensin and I1 endothelin in matrix protein production and renal sclerosis
22. Expression of transforming growth factor-beta and type IV collagen in the renal tubulointerstitium in experimental diabetes: Effects of angiotensin converting enzyme inhibition
23. The tubulointerstitium in progressive diabetic kidney disease: More than an aftermath of glomerular injury?
24. Glomerular hemodynamics in experimental diabetes mellitus
25. Effect of puberty on initial renal growth and rise in kidney insulin-like growth factor 1 in diabetic rats
26. Predmoninace of hemodynamic rather than metabolic factors in the pathogenesis of diabetic nephropathy
27. The case for intrarenal hypertension in the initiation and progression of diabetic and other glomerulopathies
28. Glomerular hemodynamic and structural alterations in experimental diabetes mellitus
29. Renal hypertrophy in experimental diabetes: Relation to severity of diabetes
30. Kidney tissue somatomedin C and initial renal growth in diabetic and uninephrectomised rats
31. Increased kidney size and glomerular filtration in untreated juvenile diabetes: Normalization by insulin treatment
32. Renin and angiotensinogen gene expression in experimental diabetes mellitus
33. Renal renin-angiotensin system in diabetes: Functional, immunohistochemical, and molecular biological correlations
34. The renin-angiotensin System in streptozotocin-induced diabetes mellitus in the rat
35. Reduced glomerular angiotensin II receptor density in early untreated diabetes mellitus in the rat
36. Angiotensin responsiveness in hyperfiltering and nonhyperfiltering diabetic rats
37. Pathological expression of renin angiotensin 11 in the renal tubule after subtotal nephrectomy. Implications for the pathogenesis of tubulointerstitial fibrosis
38. Molecular mechanisms of glucose action on angiotensinogen gene expression in rat proximal tubular cells
39. Increased bradykinin and 'normal' angiotensin peptide levels in diabetic Sprague-Dawley and transgenic (mRen-2)27 rats
40. Serum total renin is increased before microalbuminuria in diabetes
41. Preferential elevation of protien kinase C isoform beta II and diacygiycerol levels in the aorta and heart of diabetic rats: Differential reversibility to glycemic control by islet cell transplantation
42. Intracellular signalling by hydrolysis of phospholipids and activation of protein kinase C
43. Increased endothelial albumin permeability mediated by protein kinase C activation
44. Protein kinase C in diabetic nephropathy
45. Amelioration of vascular function in diabetic rats by an oral PKC beta inhibitor
46. Advanced glycosylation end products in diabetic renal and vascular disease
47. Retardation by aminoguanidine of development of albuminuria, mesangial expansion and tissue fluorescence in streptozotocin induced diabetic rat
48. Effect of diabetes and aminoguanidine therapy on renal advanced glycation end-product binding
49. Expression of receptors for advanced glycosylated end-products in renal disease
50. Extracellular matrix and its interactions in the diabetic kidney: A molecular biological approach
51. High glucose concentration causes a decrease in mesangium degradittion - A factor in the pathogenesis of diabetic nephropathy
52. Role of transforming growth factor beta in diabetic nephropathy
53. Quantification of glomerular TGF-beta-1 mRNA in patients with diabetes mellitus
54. Effects of enalapril on endothelin-1 and growth factor gene expression in diabetic rat glomeruli
55. Epidermal growth factor in renal hypertrophy in streptozotocin-diabetlc rats
56. Increased epidermal growth factor (EGF) synthesis in experimental diabetes
57. Heparin binding epidermal growth factor like growth factor is increased in diabetes related renal growth
58. Glycemic control anti the rate of progression of early diabetic kidney disease: A nine year longitudinal study
59. Molecular mechanisms of diabetic renal hypertrophy
60. Suppression of transforming growth factor beta and vascular endothelial growth factor in diabetic nephropathy in rats by a novel advanced glycation end product inhibitor, OPB-9195
61. High glucose stimulates proliferation and collagen type 1 synthesis in renal cortical fibroblasts: Mediation by autocrine activation of TGF-beta
62. Hyperglycemia and diabetic kidney disease. The case for transforming growth factor-beta as a key mediator
63. Renal expression of transforming growth factor-beta inducible gene-h3 (beta ig-h3) in normal and diabetic rats
64. The effect of intensive treatment on the development and progression of long-term complications in insulin-dependent diabetes mellitus
65. Prevention of diabetic glomerulopathy in streptozotocin diabetic rats by insulin treatment. The mesangial regions
66. Effects of pancreatic islet transplantation on the increased urinary albumin excretion rates in intact and uninephrectomised rats with diabetes mellitus
67. Urinary excretion of albumin and total protein in normal and streptozotocin diabetic rats
68. Reversal of glomerular hyperfiltration and renal hypertrophy by blood glucose normalization in diabetic rats
69. Amelioration of mesangial Volume and surface alterations following islet transplantation in diabetic rats
70. Reversal of mesangial enlargement in rats with long standing diabetes by whole pancreas transplantation
71. Intercapillary glomerulosclerosis. A syndrome of diabetes, hypertension and albuminuria
72. Factors in the aetiology of diabetic glomerulosclerosis
73. Intercapillary glomerulosclerosis: A clinical study of 100 anatomically proven cases
74. Diabetic nephropathy: A clinical and pathological study based on renal biopsies
75. The natural history of diabetic renal disease
76. Albuminuria and 24-h ambulatory blood pressure in normoalbuminuric and microalbuminuric NIDDM patients. A longitudinal study
77. Prevalence of microalbuminuria, arterial hypertension, retinopathy and neuropathy in patients with insulin-dependent diabetes
78. The effects of Goldblatt hypertension on development of the glomerular lesions of diabetes mellitus in the rat
79. Effect of captopril on blood pressure and kidney function in normotensive insulin-dependent diabetics with nephropathy
80. Prevention of diabetic glomerulopathy by pharmacological amelioration of glomerular capillary hypertension
81. Nephropathy in a model combining genetic hypertension with experimental diabetes: Enalapril versus hydralazine and metoprolol therapy
82. The effects of perindopril and triple therapy in a normotensive model of diabetic nephropathy
83. Morphometric detection of incipient glomerular lesions in diabetic nephropathy in rats. Protective effects of ACE inhibition
84. Evidence that an angiotensin-converting enzyme inhibitor has a different effect on glomerular injury according to the different phase of the disease at which treatment is started
85. Genetic hypertension accelerates nephropathy in the streptozotocin diabetic rat
86. Short- and long-term effect of angiotensin II receptor blockade in rats with experimental diabetes
87. Antihypertensive and renal-protective effects of losartan in streptozotocin diabetic rats
88. Effects of endothelin angiotensin II receptor blockade on diabetes in the transgenic (mRen-2) 27 rat
89. The role of angiotensin II and bradykinin in experimental diabetic nephropathy: Functional and structural studies
90. Comparison of effects of ACE inhibition with calcium channel blockade on renal disease in a model combining genetic hypertension with diabetes
91. Nifedipine versus fosinopril in uninephrectomized diabetic rats
92. Effect of antihypertensive therapy on the kidney in patients with diabetes: A meta-regression analysis
93. Understanding the nature of renal disease progression
94. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes - UKPDS 39
95. Gene expression for endothelinsand their receptors in glomeruli of diabetic rats
96. Induction of endothelin-1 gene by angiotensin and vasopressin in endothelial cells
97. Effect of a specific endothelin receptor antagonist on mRNA levels for extracellular matrix components and growth factors in diabetic glomeruli
98. Unselective inhibition of endothelin receptors reduces renal dysfunction in experimental diabetes
99. Aminoguanidine decreases urinary albumin and high molecular weight proteins in diabetic rats
100. Aminoguanidine ameliorates albuminuria in diabetic hypertensive rats
101. Effects of aminoguanidine in preventing experimental diabetic nephropathy are related to the duration of treatment
102. Salt restriction reduces hyperfiltration, renal enlargement and albuminuria in experimental diabetes
103. Role of hyperlipidaemia in progressive renal disease: Focus on diabetic nephropathy
104. Inhibitory effect of a growth hormone receptor antagonist (G120K-PEG) on renal enlargement, glomerular hypertrophy, and urinary albumin excretion in experimental diabetes in mice
105. Neutralization of TGF-beta by anti-TGF-beta antibody attenuates kidney hypertrophy and the enhanced extracellular matrix gene expression in STZ-induced diabetic mice